MGMT methylation status was the first predictive biomarker identified in glioma patients [40]; additionally, Hegi et al. found that epigenetic silencing of MGMT was correlated with longer patient survival when treated with alkylating agents and radiotherapy [39]. The gene discussed is MGMT; the disease is glioma.